NK cells modified with a chimeric receptor that fused NKG2D to CD3ζ (NKG2D.ζ) eliminated myeloid-derived suppressor cells (MDSC) and the anti-cancer activity of these modified NK cells was not suppressed by the tumor microenvironment (TME) (31). This evidence concerns the gene KLRK1 and cancer.